Loading quotes...

Forecast

Buy	21
Hold	3
Sell	0

News Go to news feed

Argenx posts high Vyvgart revenues, operating result below analysts' expectations

In the third quarter Argenx's revenue rose by over 50% year-on-year to $1.72 billion thanks to Vyvgart; operating income climbed to $486 million but missed the Bloomberg consensus. Net income attributable to shareholders was $506 million due to a tax effect. Higher R&D and commercialization costs and a recent trial termination in Sjögren’s weigh on the stock, which turned positive after initial losses. Argenx plans a label expansion for Vyvgart Hytrulo and a regulatory study in dermatomyositis; Efgartigimod Alfa remains the main source of revenue. » More on finanzen.net
arGEN-X: revenue boom driven by Vyvgart, earnings hit by higher R&D and sales expenses

In the third quarter arGEN-X’s revenue rose by more than 50% to $1.72 billion, almost entirely driven by sales of the drug Vyvgart. Operating income grew 40% year-on-year to $486 million but fell short of analysts’ expectations. The main reasons for margin pressure are increased research and marketing costs. Net income attributable to shareholders was $506 million, up from $344 million a year earlier. CEO Karen Massey emphasizes that Vyvgart is the business foundation and that further growth opportunities exist. » More on finanzen.net
Argenx shares recover slightly after phase-III trial flop

European stocks extended their recovery on Monday, supported by an agreement between Europe and China on export restrictions for hybrid cars, which could particularly benefit auto stocks. The EuroStoxx 50 rose 0.45 percent, the SMI gained 0.66 percent and the FTSE 100 climbed 0.99 percent. Argenx shares added 0.7 percent after having fallen sharply following the failure of a pivotal phase-III study. Ahold Delhaize fell nearly three percent after reports of IT problems and resulting security measures. » More on finanzen.net

Financials

In the last quarter, Argenx SE had revenue of €2.41bn and net profit of €718.88m

(EUR)	June 2026	YoY
Revenue	2.41bn	-
Gross profit	2.18bn	-
Net profit	718.88m	-
EBITDA	740.33m	-

Fundamentals

Metric	Value
Market capitalization	€44.28bn
Number of shares	62.89m
52-week high/low	€908.87 - €631.51
Dividends	No
Beta	-0.02
P/E ratio	31.74
PEG ratio	0.09
P/B ratio	6.47
P/S ratio	10.62

Company profile

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.